|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OVOS2 |
Gene summary for OVOS2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OVOS2 | Gene ID | 144203 |
| Gene name | alpha-2-macroglobulin like 1 pseudogene | |
| Gene Alias | OVOS2 | |
| Cytomap | 12p11.21 | |
| Gene Type | pseudo | GO ID | GO:0006508 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 144203 | OVOS2 | GSM4909281 | Human | Breast | IDC | 3.30e-12 | -5.66e-01 | 0.21 |
| 144203 | OVOS2 | GSM4909282 | Human | Breast | IDC | 1.49e-12 | -5.66e-01 | -0.0288 |
| 144203 | OVOS2 | GSM4909285 | Human | Breast | IDC | 7.27e-12 | -5.66e-01 | 0.21 |
| 144203 | OVOS2 | GSM4909286 | Human | Breast | IDC | 1.49e-12 | -5.66e-01 | 0.1081 |
| 144203 | OVOS2 | GSM4909287 | Human | Breast | IDC | 1.12e-14 | -5.66e-01 | 0.2057 |
| 144203 | OVOS2 | GSM4909288 | Human | Breast | IDC | 1.24e-02 | -5.66e-01 | 0.0988 |
| 144203 | OVOS2 | GSM4909290 | Human | Breast | IDC | 3.25e-10 | -5.66e-01 | 0.2096 |
| 144203 | OVOS2 | GSM4909291 | Human | Breast | IDC | 4.44e-08 | -5.66e-01 | 0.1753 |
| 144203 | OVOS2 | GSM4909293 | Human | Breast | IDC | 1.60e-11 | -5.66e-01 | 0.1581 |
| 144203 | OVOS2 | GSM4909294 | Human | Breast | IDC | 3.30e-12 | -5.66e-01 | 0.2022 |
| 144203 | OVOS2 | GSM4909295 | Human | Breast | IDC | 4.00e-06 | -5.66e-01 | 0.0898 |
| 144203 | OVOS2 | GSM4909296 | Human | Breast | IDC | 7.27e-12 | -5.66e-01 | 0.1524 |
| 144203 | OVOS2 | GSM4909297 | Human | Breast | IDC | 6.74e-13 | -5.66e-01 | 0.1517 |
| 144203 | OVOS2 | GSM4909298 | Human | Breast | IDC | 3.30e-12 | -5.66e-01 | 0.1551 |
| 144203 | OVOS2 | GSM4909299 | Human | Breast | IDC | 1.49e-12 | -5.66e-01 | 0.035 |
| 144203 | OVOS2 | GSM4909300 | Human | Breast | IDC | 2.78e-05 | -5.66e-01 | 0.0334 |
| 144203 | OVOS2 | GSM4909301 | Human | Breast | IDC | 6.74e-13 | -5.66e-01 | 0.1577 |
| 144203 | OVOS2 | GSM4909302 | Human | Breast | IDC | 1.89e-14 | -5.66e-01 | 0.1545 |
| 144203 | OVOS2 | GSM4909303 | Human | Breast | IDC | 3.82e-03 | -5.66e-01 | 0.0438 |
| 144203 | OVOS2 | GSM4909304 | Human | Breast | IDC | 3.04e-13 | -5.66e-01 | 0.1636 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00525479 | Breast | Precancer | regulation of peptidase activity | 71/1080 | 461/18723 | 2.72e-14 | 6.94e-12 | 71 |
| GO:00525489 | Breast | Precancer | regulation of endopeptidase activity | 67/1080 | 432/18723 | 1.06e-13 | 2.36e-11 | 67 |
| GO:00458619 | Breast | Precancer | negative regulation of proteolysis | 50/1080 | 351/18723 | 2.99e-09 | 2.39e-07 | 50 |
| GO:00513468 | Breast | Precancer | negative regulation of hydrolase activity | 50/1080 | 379/18723 | 3.85e-08 | 2.34e-06 | 50 |
| GO:00104668 | Breast | Precancer | negative regulation of peptidase activity | 38/1080 | 262/18723 | 1.46e-07 | 7.82e-06 | 38 |
| GO:00109519 | Breast | Precancer | negative regulation of endopeptidase activity | 37/1080 | 252/18723 | 1.55e-07 | 8.05e-06 | 37 |
| GO:005254714 | Breast | IDC | regulation of peptidase activity | 96/1434 | 461/18723 | 7.58e-20 | 6.15e-17 | 96 |
| GO:005254814 | Breast | IDC | regulation of endopeptidase activity | 88/1434 | 432/18723 | 1.20e-17 | 4.85e-15 | 88 |
| GO:004586114 | Breast | IDC | negative regulation of proteolysis | 70/1434 | 351/18723 | 8.21e-14 | 2.22e-11 | 70 |
| GO:005134613 | Breast | IDC | negative regulation of hydrolase activity | 71/1434 | 379/18723 | 1.33e-12 | 2.90e-10 | 71 |
| GO:001046613 | Breast | IDC | negative regulation of peptidase activity | 56/1434 | 262/18723 | 1.39e-12 | 2.92e-10 | 56 |
| GO:001095112 | Breast | IDC | negative regulation of endopeptidase activity | 52/1434 | 252/18723 | 3.53e-11 | 5.57e-09 | 52 |
| GO:005254723 | Breast | DCIS | regulation of peptidase activity | 88/1390 | 461/18723 | 1.18e-16 | 4.78e-14 | 88 |
| GO:005254823 | Breast | DCIS | regulation of endopeptidase activity | 83/1390 | 432/18723 | 6.07e-16 | 2.15e-13 | 83 |
| GO:004586123 | Breast | DCIS | negative regulation of proteolysis | 63/1390 | 351/18723 | 4.39e-11 | 6.06e-09 | 63 |
| GO:005134623 | Breast | DCIS | negative regulation of hydrolase activity | 64/1390 | 379/18723 | 4.32e-10 | 4.80e-08 | 64 |
| GO:001046622 | Breast | DCIS | negative regulation of peptidase activity | 49/1390 | 262/18723 | 1.54e-09 | 1.43e-07 | 49 |
| GO:001095122 | Breast | DCIS | negative regulation of endopeptidase activity | 47/1390 | 252/18723 | 3.63e-09 | 3.11e-07 | 47 |
| GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
| GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OVOS2 | SNV | Missense_Mutation | rs575105644 | c.1301N>T | p.Thr434Met | p.T434M | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A1-A0SQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD | |
| OVOS2 | SNV | Missense_Mutation | novel | c.1682N>G | p.Ser561Cys | p.S561C | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A4SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| OVOS2 | SNV | Missense_Mutation | novel | c.3911N>T | p.Asn1304Ile | p.N1304I | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OVOS2 | SNV | Missense_Mutation | novel | c.3526N>C | p.Ser1176Pro | p.S1176P | protein_coding | tolerated(0.2) | benign(0.059) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OVOS2 | SNV | Missense_Mutation | novel | c.2591N>G | p.Glu864Gly | p.E864G | protein_coding | deleterious(0.02) | benign(0.085) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OVOS2 | SNV | Missense_Mutation | novel | c.2738C>T | p.Ala913Val | p.A913V | protein_coding | tolerated(0.2) | benign(0.062) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OVOS2 | SNV | Missense_Mutation | rs766147973 | c.1604N>A | p.Ser535Asn | p.S535N | protein_coding | deleterious(0.01) | benign(0.331) | TCGA-C8-A1HO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| OVOS2 | SNV | Missense_Mutation | novel | c.1972N>T | p.Leu658Phe | p.L658F | protein_coding | deleterious(0) | possibly_damaging(0.668) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD | |
| OVOS2 | SNV | Missense_Mutation | novel | c.3767N>A | p.Ser1256Asn | p.S1256N | protein_coding | tolerated(0.33) | benign(0.027) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| OVOS2 | SNV | Missense_Mutation | rs768533407 | c.2093N>T | p.Pro698Leu | p.P698L | protein_coding | tolerated(0.05) | benign(0.046) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |